Challenges in antimicrobial susceptibility testing interpretation: Fluoroquinolone susceptibility discordance

被引:0
作者
Jones, Nathan [1 ]
Shah, Punit J. [2 ]
机构
[1] Houston Methodist Hosp, Dept Pharm, Houston, TX 77030 USA
[2] Houston Methodist Sugar Land Hosp, Dept Pharm, Sugar Land, TX USA
关键词
antimicrobial; breakpoints; fluoroquinolone; susceptibility;
D O I
10.1093/ajhp/zxac039
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:829 / 830
页数:2
相关论文
共 3 条
[1]  
Clinical and Laboratory Standards Institute (CLSI), 2019, CLSI rationale document MR02
[2]  
Food and Drug Administration, 2021, FDA REC ANT SUSC TES
[3]   Quinolone antibiotics [J].
Pham, Thu D. M. ;
Ziora, Zyta M. ;
Blaskovich, Mark A. T. .
MEDCHEMCOMM, 2019, 10 (10) :1719-1739